Calidi Biotherapeutics (CLDI) Non Operating Investment Income (2022 - 2023)
Calidi Biotherapeutics (CLDI) posted quarterly Non Operating Investment Income of $12848.0 for Q2 2023, down 54.09% quarter-over-quarter from $27986.0 in Q1 2023.
Calidi Biotherapeutics (CLDI) Non Operating Investment Income (2022 - 2023) Analysis & Trends
Calidi Biotherapeutics' Non Operating Investment Income history runs 2 years deep, the most recent figure standing at $12848.0 for Q2 2023.
- In Q2 2023, Non Operating Investment Income changed N/A year-over-year to $12848.0; the TTM figure through Jun 2023 stood at $40834.0 (changed N/A YoY), while the FY2025 annual figure was $244000.0, changed N/A from the prior year.
- Non Operating Investment Income for Q2 2023 stood at $12848.0, down from $27986.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $27986.0 in Q1 2023, with the low at $2266.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 12,848.00 |
| Jun 30, 2023 | 12,848.00 |
| Mar 31, 2023 | 27,986.00 |
| Mar 31, 2023 | 27,986.00 |
| Mar 31, 2022 | 2,266.00 |
| Mar 31, 2022 | 2,266.00 |